Larimar Therapeutics, Inc. (LRMR) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Bala Cynwyd, PA, United States. El CEO actual es Carole S. Ben-Maimon.
LRMR tiene fecha de IPO 2014-06-19, 65 empleados a tiempo completo, cotiza en el NASDAQ Global Market, una capitalización de mercado de $416.77M.
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
